Search Results - "Nahotko, Dominik"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
  2. 2
  3. 3

    Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6 by Chryplewicz, Agnieszka, Tienda, Samantha M., Nahotko, Dominik A., Peters, Pamela N., Lengyel, Ernst, Eckert, Mark A.

    Published in Scientific reports (26-03-2019)
    “…Emerging evidence has indicated that high-grade serous ovarian cancer (HGSOC) originates in the fallopian tube, where the earliest known genetic lesion is the…”
    Get full text
    Journal Article
  4. 4

    An engineered ultra‐high affinity Fab‐Protein G pair enables a modular antibody platform with multifunctional capability by Slezak, Tomasz, Bailey, Lucas J., Jaskolowski, Mateusz, Nahotko, Dominik A., Filippova, Ekaterina V., Davydova, Elena K., Kossiakoff, Anthony A.

    Published in Protein science (01-01-2020)
    “…Engineered recombinant antibody‐based reagents are rapidly supplanting traditionally derived antibodies in many cell biological applications. A particularly…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Non‐apoptotic caspase activation preserves Drosophila intestinal progenitor cells in quiescence by Arthurton, Lewis, Nahotko, Dominik Antoni, Alonso, Jana, Wendler, Franz, Baena‐Lopez, Luis Alberto

    Published in EMBO reports (03-12-2020)
    “…Caspase malfunction in stem cells often precedes the appearance and progression of multiple types of cancer, including human colorectal cancer. However, the…”
    Get full text
    Journal Article
  7. 7

    Abstract A39: Role of LARP1 in the leukemogenesis of Acute Myeloid Leukemia by Nahotko, Dominik A, Baran, Aneta H, Fischietti, Mariafausta, Beauchamp, Elspeth M, Platanias, Leonidas C

    Published in Blood cancer discovery (01-05-2023)
    “…Abstract Mammalian target of rapamycin (mTOR) is a strong driver of tumorigenesis in multiple types of tumors, however targeting mTOR for cancer therapy has…”
    Get full text
    Journal Article
  8. 8
  9. 9